10x Genomics, which provides a single-cell sequencing platform for biomedical research, raised $390 million by offering 10 million shares at $39, above the upwardly revised range of $36 to $38. The company had originally filed to sell 9 million shares at a range of $31 to $35. At the IPO price, the company raised 18% more in proceeds than previously anticipated and commands a fully diluted market value of $4.2 billion.
10x Genomics plans to list on the Nasdaq under the symbol TXG. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as lead managers on the deal.
The article 10x Genomics prices upsized IPO above the upwardly revised range at $39 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.